SCHEMBL25933932

SCHEMBL25933932

c1cc(CNc2cncc(-c3ccc4[nH]ncc4c3)c2)cc(-c2cccc(CNc3ncc(-c4ccc5[nH]ncc5c4)cn3)c2)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DYRK1A Q13627 8/20 0.50
▸ CLK1 P49759 8/20 0.50
▸ CLK4 Q9HAZ1 7/20 0.50
▸ CLK2 P49760 6/20 0.50
▸ DYRK1B Q9Y463 5/20 0.50
▸ CDK2 P24941 4/20 0.50
▸ CLK3 P49761 3/20 0.50
▸ CCNC P24863 1/20 0.49
▸ CDK8 P49336 1/20 0.49
▸ ROCK2 O75116 4/20 0.48
▸ GSK3B P49841 3/20 0.48
▸ DYRK3 O43781 1/20 0.45
▸ CDK5 Q00535 1/20 0.45
▸ CDK5R1 Q15078 1/20 0.45
▸ DYRK2 Q92630 1/20 0.45
▸ AURKB Q96GD4 2/20 0.44
▸ RPS6KB1 P23443 2/20 0.44
▸ CDC7 O00311 1/20 0.44
▸ CCNE1 P24864 1/20 0.44
▸ DBF4 Q9UBU7 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25934074 0.92 CLK4 (0.50) DYRK1ACLK1CLK4CLK2DYRK1B
SCHEMBL24137563 0.86 CCNC (0.61) DYRK1ACLK1CLK4CLK2DYRK1B
SCHEMBL24137561 0.82 ROCK2 (0.63) DYRK1ACLK1CLK4CLK2DYRK1B
SCHEMBL24137567 0.79 DYRK1A (0.56) DYRK1ACLK1CLK4CLK2DYRK1B
SCHEMBL24137530 0.77 FGFR1 (0.56) DYRK1ACLK1CLK4CLK2DYRK1B
SCHEMBL24137467 0.76 KCNH2 (0.49) DYRK1ACLK4CLK2CDK2CCNC
SCHEMBL24137909 0.75 CCNC (0.54) DYRK1ACLK1CLK4CLK2DYRK1B
SCHEMBL25936162 0.75 CCNC (0.54) DYRK1ACLK1CLK4CLK2DYRK1B
SCHEMBL24137732 0.75 CCNC (0.54) DYRK1ACLK1CLK4CLK2DYRK1B
SCHEMBL25933934 0.75 CCNC (0.44) DYRK1ACLK1CLK4CLK2DYRK1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230234935-A1 KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI 2023-07-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230234935-A1 KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE PACSIN2, MAP3K20, PHKG1 DYRK1A 495/4885CLK1 82/4885CLK4 176/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback